Meeting ReportIn vitro and In vivo Oncology
Preclinical evaluation of 89Zr-Df-labeled anti-VISTA antibody CI-8993
Ingrid Burvenich, Christian Wichmann, Alexander McDonald, Fiona Scott, Nancy Guo, Angela Rigopoulos, Raul Soikes, Steven Angelides, Reinhard von Roemeling and Andrew Scott
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 4030;
Ingrid Burvenich
1Olivia Newton-John Cancer Research Institute
Christian Wichmann
1Olivia Newton-John Cancer Research Institute
Alexander McDonald
1Olivia Newton-John Cancer Research Institute
Fiona Scott
1Olivia Newton-John Cancer Research Institute
Nancy Guo
1Olivia Newton-John Cancer Research Institute
Angela Rigopoulos
2Enter an organization
Raul Soikes
3Curis Inc.
Steven Angelides
3Curis Inc.
Reinhard von Roemeling
4Curis
Andrew Scott
5Austin Hospital

Article Figures & Data
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
Preclinical evaluation of 89Zr-Df-labeled anti-VISTA antibody CI-8993
Ingrid Burvenich, Christian Wichmann, Alexander McDonald, Fiona Scott, Nancy Guo, Angela Rigopoulos, Raul Soikes, Steven Angelides, Reinhard von Roemeling, Andrew Scott
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4030;
Preclinical evaluation of 89Zr-Df-labeled anti-VISTA antibody CI-8993
Ingrid Burvenich, Christian Wichmann, Alexander McDonald, Fiona Scott, Nancy Guo, Angela Rigopoulos, Raul Soikes, Steven Angelides, Reinhard von Roemeling, Andrew Scott
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4030;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.